Huntington Disease Treatments

Find Huntington Disease Treatments

Brand Name

Xenazine

Generic Name
Tetrabenazine
View Brand Information
FDA approval date: November 24, 2008
Classification: Vesicular Monoamine Transporter 2 Inhibitor
Form: Tablet

What is Xenazine (Tetrabenazine)?

XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease. XENAZINE is a vesicular monoamine transporter 2 inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study.
Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review study.
Journal: Journal of Huntington's disease
Published: August 14, 2026
Vesicular Monoamine Transporters at the Crossroads of Structure and Function: Advances, Challenges, and Future Perspectives.
Vesicular Monoamine Transporters at the Crossroads of Structure and Function: Advances, Challenges, and Future Perspectives.
Journal: Annual review of pharmacology and toxicology
Published: August 07, 2026
Perceptions on the diagnosis and treatment of patients with tardive dyskinesia: a cross-sectional survey among physicians in Italy.
Perceptions on the diagnosis and treatment of patients with tardive dyskinesia: a cross-sectional survey among physicians in Italy.
Journal: Rivista di psichiatria
Published: July 21, 2026
View All Latest Advances